Abstract 46P
Background
Checkpoint inhibitors have revolutionized treatment outcomes of several types of cancer. However, their administration is associated with unpredictable immune-related adverse events (irAEs). The objective of this study is to assess the potential predictive value of immune cells in peripheral blood for anticipating irAEs.
Methods
We prospectively enrolled patients with metastatic cancer treated with PD-1 inhibitors (nivolumab or pembrolizumab). Patients were recruited between 2017 and 2021 at the Masaryk Memorial Cancer Institute (Czech Republic). Before starting immunotherapy we performed immunoprofiling of key regulators and effectors of the immune system from peripheral blood cells using flow cytometry. We compared differences between patients who did not develop any or only mild grade (G) 1 irAE and patients who experienced clinically relevant irAE, specifically G2 and higher.
Results
We consecutively enrolled 63 patients. The median age was 66 years, with 19 (30.2 %) being female. Histological tumor types included 31 patients with melanoma, 22 with non-small cell lung cancer, 8 with renal carcinoma, and 5 with other malignancies. The majority of patients initiated treatment as first-line therapy (35 patients, 53 %). Out of these patients, 39 (61.9%) did not experience any irAEs, while 14 patients had G1 toxicity (22.2%), 10 patients (15.9%) had G2 toxicity, and 1 patient (1.6%) had G3 toxicity. G4 or G5 toxicity was not observed. Using the Mann-Whitney test, we determined that patients who did not experience any or mild (G1) immunologically mediated toxicity during treatment had significantly lower level of T helper lymphocytes CD4+ in peripheral blood before the initiation of treatment (P=0.034) compared to patients who experienced G2 or G3 toxicity during treatment. Additionally, they had lower level of naive T lymphocytes CD4+RO-CD27+ (P=0.012), lower level myeloid dendritic cells CD4-HLADR+ (P=0.040), and higher level of memory lymphocytes CD4+RO+CD27+ (P=0.006).
Conclusions
Our results support the hypothesis that initial flow cytometry parameters detectable in peripheral blood could significantly predict irAE. These findings need to be validated in a larger patient population.
Legal entity responsible for the study
The authors.
Funding
Ministry of Health of the Czech Republic, grant nr. NV18-03-00339.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
14P - Integrated modelling of T cell repertoires to identify clonotype signatures of ICI response
Presenter: Juan Luis Melero
Session: Poster Display
16P - Exosomal PD-L1 and lactate predict clinical outcomes of PD-1 blockade combined with chemotherapy in advanced-stage gastric and gastroesophageal junction adenocarcinoma
Presenter: Yongshun Chen
Session: Poster Display
17P - Spatial Characteristics Associated with the Chemo and Immuno-treatment Response of Gastric Cancer Revealed by Multi-omics Analysis
Presenter: Gang Che
Session: Poster Display
18P - Association of DNA methylation profiles with pathologic complete response in early triple negative breast cancer patients receiving neoadjuvant chemoimmunotherapy
Presenter: Angelika Starzer
Session: Poster Display
19P - The prognostic value of soluble CD73 in advanced triple-negative breast cancer: an exploratory analysis of the SYNERGY trial
Presenter: Denis Zoë
Session: Poster Display
21P - Mass cytometry reveals a population of exhausted CD8+ T cells associated with durvalumab/tremelimumab/vinorelbine efficacy in advanced cervical cancer (iMOVIE).
Presenter: Alexandre Bertucci
Session: Poster Display
22P - Predictive value of Tertiary Lymphoid Structure in patients with mismatch repair deficient advanced/ recurrent endometrial cancer treated with Dostarlimab.
Presenter: Maria Kfoury
Session: Poster Display
23P - Circulating immune cells and activity of immune checkpoint inhibitors in metastatic renal cell carcinoma
Presenter: Ronan Flippot
Session: Poster Display
24P - Chromosome 3p-related gene alterations (GA) as biomarkers for immunocombinations in metastatic renal cell carcinoma (mRCC): a hypothesis-generating analysis
Presenter: Matteo Rosellini
Session: Poster Display